David R. Magnin
Bristol-Myers Squibb
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by David R. Magnin.
Bioorganic & Medicinal Chemistry Letters | 2003
David R. Magnin; Scott A. Biller; John R. Wetterau; Jeffrey A. Robl; John K. Dickson; Prakash Taunk; Thomas Harrity; R. Michael Lawrence; Chongqing Sun; Tammy C. Wang; Janette V. H. Logan; Olga M. Fryszman; Fergal Connolly; Kern Jolibois; Lori Kunselman
A series of newly synthesized phosphonate esters were evaluated for their effects on microsomal triglyceride transfer protein activity (MTP). The most potent compounds were evaluated for their ability to inhibit lipoprotein secretion in HepG2 cells and to affect VLDL secretion in rats. These inhibitors were also found to lower serum cholesterol levels in a hamster model upon oral dosing.
Analytical Biochemistry | 2003
Aiying Wang; Yanting Huang; Prakash Taunk; David R. Magnin; Krishnendu Ghosh; James G. Robertson
Using available commercial robotics and instrumentation, we developed a fully automated and rigorous steady state enzyme kinetic assay for dipeptidyl peptidase IV (DPP IV; E.C. 3.4.14.5). The automated assay was validated with isoleucyl thiazolidide, a potent inhibitor of DPP IV with K(is)=110nM. Signal window analysis indicated that the assay had a 98% probability of detecting an inhibitor yielding 15% inhibition, with a predicted false positive rate of 0.13%. A mechanistic inhibition version of the automated assay was validated with isoleucyl 4-cyanothiazolidide, a very potent inhibitor of DPP IV. Isoleucyl 4-cyanothiazolidide was a competitive inhibitor of purified porcine DPP IV with K(is)=1 nM. Similar K(is) values were obtained for purified rat DPP IV and for DPP IV activity in human plasma from normal and diabetic donors. The pH dependence of K(is) for isoleucyl 4-cyanothiazolidide yielded a bell-shaped profile, with pK(a)=5.0 and pK(b)=7.6. To date, over 100,000 data points have been generated in profiling targeted compound libraries and in the analysis of tight-binding inhibitors of DPP IV. The data also show that robotic analysis is capable of producing full mechanistic inhibition analysis in a timely fashion to support drug discovery.
Journal of Medicinal Chemistry | 2005
David J. Augeri; Jeffrey A. Robl; David A. Betebenner; David R. Magnin; Ashish Khanna; James G. Robertson; Aiying Wang; Ligaya M. Simpkins; Prakash Taunk; Qi Huang; Songping Han; Benoni E. Abboa-Offei; Michael Cap; Li Xin; Li Tao; Effie Tozzo; Gustav Welzel; Donald M. Egan; Jovita Marcinkeviciene; Shu Y. Chang; Scott A. Biller; Mark S. Kirby; Rex A. Parker; Lawrence G. Hamann
Science | 1998
John R. Wetterau; Richard E. Gregg; Thomas Harrity; Cynthia Arbeeny; Michael Cap; Fergal Connolly; Ching-Hsuen Chu; R.J. George; David A. Gordon; Haris Jamil; Kern Jolibois; Lori Kunselman; Shih-Jung Lan; Thomas J. Maccagnan; Beverly Ricci; Mujing Yan; Douglas B. Young; Ying Chen; Olga M. Fryszman; Janette V. H. Logan; Christa L. Musial; Michael A. Poss; Jeffrey A. Robl; Ligaya M. Simpkins; William Allen Slusarchyk; Richard B. Sulsky; Prakash Taunk; David R. Magnin; Joseph A. Tino; R. Michael Lawrence
Archive | 2001
Jeffrey A. Robl; Richard B. Sulsky; David J. Augeri; David R. Magnin; Lawrence G. Hamann; David A. Betebenner
Archive | 1997
Scott A. Biller; John K. Dickson; R. Michael Lawrence; David R. Magnin; Michael A. Poss; Richard B. Sulsky; Joseph A. Tino
Archive | 1996
Scott A. Biller; John K. Dickson; R. Michael Lawrence; David R. Magnin; Michael A. Poss; Jeffrey A. Robl; William A. Slusarchyk; Richard B. Sulsky; Joseph A. Tino
Archive | 2000
Jeffrey A. Robl; Richard B. Sulsky; David R. Magnin
Archive | 1994
David R. Magnin; Scott A. Biller; John K. Dickson; R. Michael Lawrence; Richard B. Sulsky
Archive | 2003
Truc Chi Vu; David B. Brzozowski; Rita Fox; Jollie Duaine Godfrey; Ronald L. Hanson; Sergei V. Kolotuchin; John A. Mazzullo; Ramesh N. Patel; Jianji Wang; Kwok Wong; Jurong Yu; Jason Zhu; David R. Magnin; David J. Augeri; Lawrence G. Hamann